Skip to Content

Posts tagged with "Why Everyone Loves Us"

  • Drug Prices

    Shkreli, Turing, and PhRMA

    There have been a few developments in the Turing Pharmaceuticals affair. Martin Shkreli, after given several fantastically annoying interviews, finally reversed course and said that the company will lower the price of Daraprim (pyrimethamine). He is not, at the moment, saying what the price will be lowered to: perhaps to merely ten times the previo… Read More
  • Business and Markets

    Martin Shkreli Has One Idea, And It’s a Bad One

    Martin Shkreli may finally have overstepped, and it will be a good thing if he has. Let me back up both those statements. Shkreli, you may recall, was the founder of Retrophin, a company whose business model was to buy up obscure orphan generic drugs (such as Thiola) and immediately raise their price by, say… Read More
  • Drug Prices

    France Elbows Roche Aside on Avastin

    The potential off-label use of Avastin for wet age-related macular degeneration has been a source of many arguments over the last few years. The arguments come because another formulation of the same drug, Lucentis, is what’s actually approved for wet AMD, and it’s significantly more expensive. (The two forms appear to have basically th… Read More
  • Business and Markets

    Thiola, Retrophin, Martin Shkrell, Reddit, and More

    Well, it was not a dull evening around the In the Pipeline headquarters last night. I submitted a link to Reddit for my post yesterday about Retrophin and Thiola, and that blew up onto that site’s front page. The Corante server melted under the impact, which isn’t too surprising, since it’s struggling at the best… Read More
  • Business and Markets

    The Most Unconscionable Drug Price Hike I Have Yet Seen

    There’s a drug called Thiola (tiopronin) that most people have never heard of. It’s on my list of “smaller than aspirin” drugs, and I’d never heard of it until I put that one together. But thanks to a little company called Retrophin, we all get to hear about it now. It’s used to treat cystinuria… Read More
  • Cancer

    Incomprehensible Drug Prices? Think Again.

    There’s a post by Peter Bach, of the Center for Health Policy and Outcomes, that’s been getting a lot of attention the last few days. It’s called “Unpronounceable Drugs, Incomprehensible Prices”, and you know what it says. No, really, you do, even if you haven’t seen it. Too high, unconscionable, market can’… Read More
  • Business and Markets

    The Hep C Field Gets Nastier By the Minute

    What a mess there is in the hepatitis C world. Gilead is, famously, dominating the market with Sovaldi, whose price has set off all sorts of cost/benefit debates. The companies competing with them are scrambling to claim positions, and the Wall Street Journal says that AbbVie is really pulling out all the stops. Try this… Read More
  • Clinical Trials

    The Real Numbers on Tamiflu

    I’ve been meaning to cover this controversy about Tamiflu (oseltamivir). The Cochrane group has reviewed all the clinical data obtainable on the drug’s efficacy, and has concluded that it doesn’t have much. That’s in contrast to an earlier review they’d conducted in 2008, which said that, overall, the evidence was slig… Read More
  • Why Everyone Loves Us

    Pfizer Seeks Respect

    Here’s Ian Read of Pfizer, on that company’s reputation (and that of pharma in general): . . .many people — including not only regulators but also legislators and their constituents — have a say in how we can conduct our business. At the same time, many have a great and sometimes emotionally charged interest in… Read More
  • Clinical Trials

    Should Drug Industry Research All Get Rejected For Publication?

    If you work in the drug industry, and for some reason you feel that your blood pressure isn’t quite high enough today, a look at this debate at the British Medical Journal should fix that up for you. “Should journals stop publishing research funded by the drug industry?” is the title – there, doesn’t that… Read More
123...